General Information of Drug (ID: DMZAYYD)

Drug Name
HER2 antigen-specific cancer immunotherapeutic
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 2 [1]
Cross-matching ID
TTD ID
D04PMS

References

1 ClinicalTrials.gov (NCT01220128) Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer. U.S. National Institutes of Health.